CVA Family Office’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.91K Buy
+14
New +$1.72K ﹤0.01% 1526
2025
Q3
– Sell
-4
Closed -$498 – 1337
2025
Q2
$498 Sell
4
-3
-43% -$382 ﹤0.01% 1236
2025
Q1
$891 Buy
7
+3
+75% +$462 ﹤0.01% 1135
2024
Q4
$576 Hold
4
– – ﹤0.01% 1192
2024
Q3
$595 Buy
+4
New +$574 ﹤0.01% 1162
2022
Q2
– Sell
-60
Closed -$11K – 978
2022
Q1
$11K Hold
60
– – ﹤0.01% 665
2021
Q4
$16K Buy
+60
New +$16.2K ﹤0.01% 563
2021
Q3
– Sell
-75
Closed -$15K – 771
2021
Q2
$15K Buy
+75
New +$14.5K ﹤0.01% 585

Other funds holding RGEN

CVA Family Office's RGEN Position: Q2 2026 in Review

CVA Family Office opened a new position in Repligen (RGEN) in Q2 2026: 14 shares worth $1.91K. The stake represents ﹤0.01% of the portfolio and ranks #1526 among its holdings. This is a return to the name: CVA Family Office previously reported a position in RGEN as recently as Q2 2025.

CVA Family Office first reported a position in RGEN in Q2 2021 and has held it in 8 quarters since. The position peaked at $16K in Q4 2021. 482 funds tracked by Wall St. Rank hold RGEN as of Q2 2026.

  • CVA Family Office held 14 shares of Repligen worth $1.91K as of Q2 2026.
  • Repligen was a new CVA Family Office position in Q2 2026.
  • Repligen made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1526 holding.
  • CVA Family Office first reported a position in Repligen in Q2 2021 and has held it in 8 quarters since.
  • CVA Family Office's Repligen position peaked at $16K in Q4 2021.
  • 482 funds tracked by Wall St. Rank held Repligen as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.